[go: up one dir, main page]

NO882724D0 - Smertepreparat. - Google Patents

Smertepreparat.

Info

Publication number
NO882724D0
NO882724D0 NO882724A NO882724A NO882724D0 NO 882724 D0 NO882724 D0 NO 882724D0 NO 882724 A NO882724 A NO 882724A NO 882724 A NO882724 A NO 882724A NO 882724 D0 NO882724 D0 NO 882724D0
Authority
NO
Norway
Prior art keywords
preparation
pain preparation
tryptophan
pain
degradation inhibitor
Prior art date
Application number
NO882724A
Other languages
English (en)
Other versions
NO882724L (no
Inventor
Joachim Kamprad
Rolf Ludger
Original Assignee
Joachim Kamprad
Rolf Ludger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joachim Kamprad, Rolf Ludger filed Critical Joachim Kamprad
Publication of NO882724D0 publication Critical patent/NO882724D0/no
Publication of NO882724L publication Critical patent/NO882724L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO882724A 1986-12-13 1988-06-21 Smertepreparat. NO882724L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19863642668 DE3642668A1 (de) 1986-12-13 1986-12-13 Schmerzmittel fuer menschen
PCT/EP1987/000769 WO1988004170A1 (en) 1986-12-13 1987-12-10 Pain-killer

Publications (2)

Publication Number Publication Date
NO882724D0 true NO882724D0 (no) 1988-06-21
NO882724L NO882724L (no) 1988-10-10

Family

ID=6316147

Family Applications (1)

Application Number Title Priority Date Filing Date
NO882724A NO882724L (no) 1986-12-13 1988-06-21 Smertepreparat.

Country Status (11)

Country Link
US (1) US5216019A (no)
EP (1) EP0344158B1 (no)
JP (1) JPH0645539B2 (no)
KR (1) KR960011235B1 (no)
AT (1) ATE74505T1 (no)
AU (1) AU634149B2 (no)
CA (1) CA1320133C (no)
DE (2) DE3642668A1 (no)
DK (1) DK169120B1 (no)
NO (1) NO882724L (no)
WO (1) WO1988004170A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004039196B4 (de) * 2004-08-12 2008-07-31 Dr.Kamprad Kg Neue Formulierung für L-Tryptophan
US9173860B2 (en) 2009-11-04 2015-11-03 Susan Park Perrine S isomers of α-methyl hydrocinnamic acid for the treatment of blood disorders
DE102022103658A1 (de) 2022-02-16 2023-08-17 Joachim Kamprad Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
EP0004040B1 (en) * 1978-03-03 1983-10-05 MERCK PATENT GmbH Pharmaceutical compositions having analgesic properties comprising a compound selected from d- and dl-phenylalanine, d- and dl-leucine and hydrocinnamic acid in the unit dose of at least 200mg
JPS57160227A (en) * 1981-03-30 1982-10-02 Fujitsu Ltd Frequency synthesizer
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
GB2113545A (en) * 1982-01-22 1983-08-10 Mayron International Inc Treatment of migraine
GB2113546A (en) * 1982-01-22 1983-08-10 Mayron International Inc Treatment of migraine
US4639465A (en) * 1985-08-30 1987-01-27 Commonwealth Medical Corporation Of America Method and composition for relieving pain

Also Published As

Publication number Publication date
EP0344158B1 (de) 1992-04-08
NO882724L (no) 1988-10-10
KR960011235B1 (ko) 1996-08-21
AU1042888A (en) 1988-06-30
DE3642668A1 (de) 1988-06-23
US5216019A (en) 1993-06-01
WO1988004170A1 (en) 1988-06-16
KR890700025A (ko) 1989-03-02
CA1320133C (en) 1993-07-13
AU634149B2 (en) 1993-02-18
DK452788A (da) 1988-08-12
DE3778165D1 (no) 1992-05-14
ATE74505T1 (de) 1992-04-15
DK452788D0 (da) 1988-08-12
DK169120B1 (da) 1994-08-22
EP0344158A1 (de) 1989-12-06
JPH02500746A (ja) 1990-03-15
JPH0645539B2 (ja) 1994-06-15

Similar Documents

Publication Publication Date Title
NO904694D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO901684L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO894630L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinuklidin-derivater.
NO302366B1 (no) 4-merkaptoacetylamino-£2|benzazepinon(3)-derivater, og farmasöytisk preparat
NO880182L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,2-dihydro-3h-indazol-3-on-derivater.
NO893616L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tricykliske forbindelser.
NO883485D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinyl-isokinolinforbindelser.
NO165071C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7-(3-amino-1-pyrrolidinyl)-8-klor-1-cyklopropyl-6- fluor-1,4,-dihydro-4-okso-3-kinolin-karboksylsyre.
NO890155D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive indolpiperidin-forbindelser.
NO167734C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte aminderivater.
NO880667D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylpiperazinyl-alkylen-fenyl-heterocykliske forbindelser.
NO891723D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO895220D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzenderivater.
NO882724D0 (no) Smertepreparat.
IT8026233A0 (it) Derivato della n-acetil-cisteina ad attivita' terapeutica, procedimento per la sua preparazione e relative composizioni farmaceutiche.
NO167739C (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive ginkolid-derivater.
NO905327L (no) Fremgangsmaate for fremstilling av terapeutisk aktive karbamoylderivater.
NO894423D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive propanolaminer.
NO900972L (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO913187D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tricykliske derivater.
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
NO890724L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetraazaacenaftylen-derivater.
ES2167942T3 (es) Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes.
NO890519D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive propanon-derivater.
NO890506D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kloranilin-derivater.